| Budget Amount *help |
¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Hematopoietic stem cell transplantation (HSCT) has become the curable treatment for the patient of hematological malignancy. Graft versus host disease (GVHD) after HSCT is the most important problem. The pathology of chronic GVHD is the organ fibrosis. It declines the Quality of life after HSCT. In this study, we focused on the fibrocyte, it was precursor of fibroblast, analyzed the pathophysiology of chronic GVHD. In the study of mice model, activated monocytes were appeared to peripheral blood after 2 weeks. On the contrary, immunocompetent cells, T cell, B cell and NK cell, were appeared after 4 to 6 weeks. In the study of human, activated monocytes were appeared peripheral blood about day 30 after HSCT and these cells were detectable long time. These data suggest that activated monocytes were appeared after HSCT in early stage and the interaction of these cells to immunological cells may be related to chronic GVHD after HSCT. Further experiments are needed for more detail analysis.
|
